330 related articles for article (PubMed ID: 17957148)
1. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
3. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
[TBL] [Abstract][Full Text] [Related]
4. A polymorphism in the leptin receptor gene at position 223 is associated with growth hormone replacement therapy responsiveness in idiopathic short stature and growth hormone deficiency patients.
Su PH; Yang SF; Yu JS; Chen SJ; Chen JY
Eur J Med Genet; 2012 Dec; 55(12):682-7. PubMed ID: 23009903
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
6. Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor.
Meyer S; Ipek M; Keth A; Minnemann T; von Mach MA; Weise A; Ittner JR; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Kann PH; ;
Growth Horm IGF Res; 2007 Aug; 17(4):307-14. PubMed ID: 17462934
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
Hughes IP; Harris M; Choong CS; Ambler G; Cutfield W; Hofman P; Cowell CT; Werther G; Cotterill A; Davies PS;
Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731
[TBL] [Abstract][Full Text] [Related]
8. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
9. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
10. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
[TBL] [Abstract][Full Text] [Related]
11. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
12. Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency.
Miletta MC; Scheidegger UA; Giordano M; Bozzola M; Pagani S; Bona G; Dattani M; Hindmarsh PC; Petkovic V; Oser-Meier M; Flück CE; Mullis PE
Clin Endocrinol (Oxf); 2012 May; 76(5):683-90. PubMed ID: 22026507
[TBL] [Abstract][Full Text] [Related]
13. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
14. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
Högler W; Briody J; Moore B; Lu PW; Cowell CT
Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment.
Jorge AA; Arnhold IJ
Horm Res; 2009 Apr; 71 Suppl 2():55-63. PubMed ID: 19407498
[TBL] [Abstract][Full Text] [Related]
16. Common polymorphisms in the GH/IGF-1 axis contribute to growth in extremely tall subjects.
Hendriks AE; Brown MR; Boot AM; Oostra BA; de Jong FH; Drop SL; Parks JS
Growth Horm IGF Res; 2011 Dec; 21(6):318-24. PubMed ID: 21944866
[TBL] [Abstract][Full Text] [Related]
17. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
Hellgren G; Glad CA; Jonsson B; Johannsson G; Albertsson-Wikland K
Growth Horm IGF Res; 2015 Jun; 25(3):127-35. PubMed ID: 25742716
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone treatment in prepubertal children with celiac disease and growth hormone deficiency.
Giovenale D; Meazza C; Cardinale GM; Farinelli E; Mastrangelo C; Messini B; Citro G; Del Vecchio M; Di Maio S; Possenti I; Bozzola M
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):433-7. PubMed ID: 18030209
[TBL] [Abstract][Full Text] [Related]
19. Impact of overweight on effectiveness of treatment with human growth hormone in growth hormone deficient children: analysis of German KIGS data.
Reinehr T; Bechtold-Dalla Pozza S; Bettendorf M; Doerr HG; Gohlke B; Hauffa BP; Kaspers S; Land C; Mehls O; Schwab KO; Stahnke N; Ranke MB;
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):544-8. PubMed ID: 22006181
[TBL] [Abstract][Full Text] [Related]
20. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
